| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64159c29baf739a677c187e55cae98e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bce595c861dba361078ba893e4713be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d8b3e5663a841e8a71b6b31a160ff9b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2009-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9aee994dcca8838497f165c116c305f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93f5f1043dc5213bebf80d096a5fcd22 |
| publicationDate |
2013-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8591921-B2 |
| titleOfInvention |
Induction of tumor hypoxia for cancer therapy |
| abstract |
Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region. The activated hypoxia-activated bioreductive agents kill tumor cells in the hypoxic region by catalyzing DNA stand breakage within the tumor cells. Because the activity is localized, side effects that typically occur as a result of systemic administration of bioreductive agents are reduced. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11207386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9649316-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10159676-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10076556-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10426779-B2 |
| priorityDate |
2008-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |